These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 32766688)
21. Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes. Ahangari N; Ghayour Mobarhan M; Sahebkar A; Pasdar A Ann Med; 2018 Jun; 50(4):303-311. PubMed ID: 29578362 [TBL] [Abstract][Full Text] [Related]
22. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. Page MM; Watts GF Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830 [TBL] [Abstract][Full Text] [Related]
23. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410 [TBL] [Abstract][Full Text] [Related]
24. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. Gebauer K; Reinecke H Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075 [TBL] [Abstract][Full Text] [Related]
25. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study. Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549 [TBL] [Abstract][Full Text] [Related]
27. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231 [TBL] [Abstract][Full Text] [Related]
28. Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies. Brandts J; Ray KK Curr Opin Lipidol; 2020 Aug; 31(4):182-186. PubMed ID: 32487819 [TBL] [Abstract][Full Text] [Related]
29. Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. Cesaro A; Gragnano F; Fimiani F; Moscarella E; Diana V; Pariggiano I; Concilio C; Natale F; Limongelli G; Bossone E; Calabrò P Eur J Prev Cardiol; 2020 Mar; 27(5):556-558. PubMed ID: 30913901 [No Abstract] [Full Text] [Related]
35. Inclisiran for the treatment of dyslipidemia. Nishikido T; Ray KK Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410 [TBL] [Abstract][Full Text] [Related]
36. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Khan SA; Naz A; Qamar Masood M; Shah R Am J Cardiol; 2020 Nov; 134():69-73. PubMed ID: 32892993 [TBL] [Abstract][Full Text] [Related]
37. PCSK9 targets important for lipid metabolism. Schulz R; Schlüter KD Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216 [TBL] [Abstract][Full Text] [Related]
38. [Risk of cardiovascular complications cut in half?]. Einecke D MMW Fortschr Med; 2015 Apr; 157(6):26. PubMed ID: 26015190 [No Abstract] [Full Text] [Related]
39. [Inclisiran - a new era in lipid-lowering therapy]. Voevoda MI; Gurevich VS; Ezhov MV; Sergienko IV Kardiologiia; 2022 Jun; 62(6):57-62. PubMed ID: 35834343 [TBL] [Abstract][Full Text] [Related]
40. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]